BACKGROUND: Although QT prolongation following myocardial infarction (MI) is generally moderate, cases with marked QT prolongation leading to life-threatening torsades de pointes (TdP) have been described. OBJECTIVE: To investigate the genetic substrate of this phenomenon. METHODS: We studied 13 patients who developed TdP in the subacute phase of MI (2-11 days) and a group of 133 ethnically matched controls with uncomplicated MI. Long QT syndrome genes and the KCNH2-K897T polymorphism were screened by using denaturing high-performance liquid chromatography plus direct sequencing and a specific TaqMan assay, respectively. RESULTS: Two of the 13 patients (15%) who presented with QT prolongation and TdP were found to carry long QT syndrome mutations (KCNH2-R744X and SCN5A-E446K). Nine of the remaining 11 patients (82%) carried the KCNH2-K897T polymorphism, which was present in 35% of the controls (P = .0035). Thus, patients with an acute MI carrying the KCNH2-K897T polymorphism had an 8-fold greater risk of experiencing TdP compared with controls (95% confidence interval = 2-40). CONCLUSIONS: Our data suggest that the common K897T polymorphism is associated with an increased risk of TdP developing in the subacute phase of MI. Our findings support the concept that the electrical remodeling associated with this healing phase of MI may unmask a genetic substrate predisposing to a time-limited development of life-threatening arrhythmias. They also provide the first line of evidence in support of the hypothesis that a common polymorphism, previously described as a modifier of the severity of LQTS, may increase the risk of life-threatening arrhythmias in a much more prevalent cardiac disease such as myocardial infarction.
BACKGROUND: Although QT prolongation following myocardial infarction (MI) is generally moderate, cases with marked QT prolongation leading to life-threatening torsades de pointes (TdP) have been described. OBJECTIVE: To investigate the genetic substrate of this phenomenon. METHODS: We studied 13 patients who developed TdP in the subacute phase of MI (2-11 days) and a group of 133 ethnically matched controls with uncomplicated MI. Long QT syndrome genes and the KCNH2-K897T polymorphism were screened by using denaturing high-performance liquid chromatography plus direct sequencing and a specific TaqMan assay, respectively. RESULTS: Two of the 13 patients (15%) who presented with QT prolongation and TdP were found to carry long QT syndrome mutations (KCNH2-R744X and SCN5A-E446K). Nine of the remaining 11 patients (82%) carried the KCNH2-K897T polymorphism, which was present in 35% of the controls (P = .0035). Thus, patients with an acute MI carrying the KCNH2-K897T polymorphism had an 8-fold greater risk of experiencing TdP compared with controls (95% confidence interval = 2-40). CONCLUSIONS: Our data suggest that the common K897T polymorphism is associated with an increased risk of TdP developing in the subacute phase of MI. Our findings support the concept that the electrical remodeling associated with this healing phase of MI may unmask a genetic substrate predisposing to a time-limited development of life-threatening arrhythmias. They also provide the first line of evidence in support of the hypothesis that a common polymorphism, previously described as a modifier of the severity of LQTS, may increase the risk of life-threatening arrhythmias in a much more prevalent cardiac disease such as myocardial infarction.
Authors: Dan Hu; Sami Viskin; Antonio Oliva; Tabitha Carrier; Jonathan M Cordeiro; Hector Barajas-Martinez; Yuesheng Wu; Elena Burashnikov; Serge Sicouri; Ramon Brugada; Rafael Rosso; Alejandra Guerchicoff; Guido D Pollevick; Charles Antzelevitch Journal: Heart Rhythm Date: 2007-04-10 Impact factor: 6.343
Authors: W H Linda Kao; Dan E Arking; Wendy Post; Thomas D Rea; Nona Sotoodehnia; Ronald J Prineas; Bryan Bishe; Betty Q Doan; Eric Boerwinkle; Bruce M Psaty; Gordon F Tomaselli; Josef Coresh; David S Siscovick; Eduardo Marbán; Peter M Spooner; Gregory L Burke; Aravinda Chakravarti Journal: Circulation Date: 2009-02-09 Impact factor: 29.690
Authors: Sami Viskin; Pieter G Postema; Zahurul A Bhuiyan; Raphael Rosso; Jonathan M Kalman; Jitendra K Vohra; Milton E Guevara-Valdivia; Manlio F Marquez; Evgeni Kogan; Bernard Belhassen; Michael Glikson; Boris Strasberg; Charles Antzelevitch; Arthur A M Wilde Journal: J Am Coll Cardiol Date: 2010-01-29 Impact factor: 24.094
Authors: Eyal Nof; Jonathan M Cordeiro; Guillermo J Pérez; Fabiana S Scornik; Kirstine Calloe; Barry Love; Elena Burashnikov; Gabriel Caceres; Moshe Gunsburg; Charles Antzelevitch Journal: Circ Cardiovasc Genet Date: 2010-02-24
Authors: Lia Crotti; Maria Cristina Monti; Roberto Insolia; Anna Peljto; Althea Goosen; Paul A Brink; David A Greenberg; Peter J Schwartz; Alfred L George Journal: Circulation Date: 2009-10-12 Impact factor: 29.690
Authors: Christopher Newton-Cheh; Mark Eijgelsheim; Kenneth M Rice; Paul I W de Bakker; Xiaoyan Yin; Karol Estrada; Joshua C Bis; Kristin Marciante; Fernando Rivadeneira; Peter A Noseworthy; Nona Sotoodehnia; Nicholas L Smith; Jerome I Rotter; Jan A Kors; Jacqueline C M Witteman; Albert Hofman; Susan R Heckbert; Christopher J O'Donnell; André G Uitterlinden; Bruce M Psaty; Thomas Lumley; Martin G Larson; Bruno H Ch Stricker Journal: Nat Genet Date: 2009-03-22 Impact factor: 38.330
Authors: Antonio Oliva; Vincenzo M Grassi; Oscar Campuzano; Maria Brion; Vincenzo Arena; Sara Partemi; Monica Coll; Vincenzo L Pascali; Josep Brugada; Angel Carracedo; Ramon Brugada Journal: Int J Legal Med Date: 2016-09-21 Impact factor: 2.686
Authors: W Victor R Vieweg; Mehrul Hasnain; Robert H Howland; Thomas Clausen; Jayanthi N Koneru; Christopher Kogut; Ericka L Breden Crouse; Jules C Hancox; Antony Fernandez; Ananda K Pandurangi Journal: Ther Adv Psychopharmacol Date: 2013-08